Cancer cachexia: understanding the molecular basis

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Nature Reviews. Cancer

• Publication date

  2014-10-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc3829PMID 25291291
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Myostatin is a novel tumoral factor that induces cancer cachexia

  2016cited by this paper
• Role of microRNAs in skeletal muscle hypertrophy

  2014cited by this paper
• Characteristics of taste and smell alterations reported by patients after starting treatment for lung cancer

  2014cited by this paper
• A switch from white to brown fat increases energy expenditure in cancer-associated cachexia.

  2014cited by this paper
• Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7

  2014cited by this paper
• Molecular imaging of brown adipose tissue in health and disease

  2014cited by this paper
• The abridged patient-generated subjective global assessment is a useful tool for early detection and characterization of cancer cachexia.

  2014cited by this paper
• Acylated and unacylated ghrelin inhibit doxorubicin‐induced apoptosis in skeletal muscle

  2014cited by this paper
• Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome.

  2014cited by this paper
• Acylated and unacylated ghrelin administration to blunt muscle wasting

  2014cited by this paper
• Elevated expression of activins promotes muscle wasting and cachexia

  2014cited by this paper
• Molecular insights into mitochondrial dysfunction in cancer-related muscle wasting.

  2014cited by this paper
• MicroRNA profiling links miR-378 to enhanced adipocyte lipolysis in human cancer cachexia.

  2014cited by this paper
• Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia

  2014cited by this paper
• Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA).

  2014cited by this paper
• Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis.

  2013cited by this paper
• Bladder cancer-induced skeletal muscle wasting: disclosing the role of mitochondria plasticity.

  2013cited by this paper
• NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia.

  2013cited by this paper
• Exercise training attenuates aging-associated mitochondrial dysfunction in rat skeletal muscle: role of PGC-1α.

  2013cited by this paper
• Abstracts of the 7th Cachexia Conference, Kobe/Osaka, Japan, December 9–11, 2013

  2013cited by this paper
• Signaling pathways controlling skeletal muscle mass

  2013cited by this paper
• Understanding the mechanisms and treatment options in cancer cachexia

  2013cited by this paper
• Cancer‐ and endotoxin‐induced cachexia require intact glucocorticoid signaling in skeletal muscle

  2013cited by this paper
• Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer

  2013cited by this paper
• Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice

  2013cited by this paper
• Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?

  2013cited by this paper
• Muscle wasting: the gut microbiota as a new therapeutic target?

  2013cited by this paper
• Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

  2013cited by this paper
• Interplay of adipokines and myokines in cancer pathophysiology: Emerging therapeutic implications.

  2013cited by this paper
• Nutritional counseling and nutritional supplements: a cornerstone of multidisciplinary cancer care for cachectic patients

  2013cited by this paper
• Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model

  2013cited by this paper
• Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target

  2013cited by this paper
• Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients.

  2013cited by this paper
• Cancer cachexia—pathophysiology and management

  2013cited by this paper
• C-Reactive Protein Levels and Vitamin D Receptor Polymorphisms as Markers in Predicting Cachectic Syndrome in Cancer Patients

  2012cited by this paper
• Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting

  2012cited by this paper
• Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats.

  2012cited by this paper
• Myostatin: more than just a regulator of muscle mass.

  2012cited by this paper
• Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice.

  2012cited by this paper
• Theophylline is able to partially revert cachexia in tumour-bearing rats

  2012cited by this paper
• Restoring Specific Lactobacilli Levels Decreases Inflammation and Muscle Atrophy Markers in an Acute Leukemia Mouse Model

  2012cited by this paper
• Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease.

  2012cited by this paper
• Counteracting inflammation: a promising therapy in cachexia.

  2012cited by this paper
• Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?

  2012cited by this paper
• Myostatin is a novel tumoral factor that induces cancer cachexia

  2012cited by this paper
• Myosin heavy chain is not selectively decreased in murine cancer cachexia

  2012cited by this paper
• Definition and classification of cancer cachexia: an international consensus.

  2011cited by this paper
• Efficiency of oxidative phosphorylation in liver mitochondria is decreased in a rat model of peritoneal carcinosis.

  2011cited by this paper
• Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

  2011cited by this paper
• Cancer Induces Cardiomyocyte Remodeling and Hypoinnervation in the Left Ventricle of the Mouse Heart

  2011cited by this paper
• CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss

  2011cited by this paper
• Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia

  2011cited by this paper
• Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity

  2011cited by this paper
• Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance

  2011cited by this paper
• Intramyocellular lipid droplets increase with progression of cachexia in cancer patients

  2011cited by this paper
• The cachexia score (CASCO): a new tool for staging cachectic cancer patients

  2011cited by this paper
• An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study

  2011cited by this paper
• Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.

  2010cited by this paper
• Evolving classification systems for cancer cachexia: ready for clinical practice?

  2010cited by this paper
• Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.

  2010cited by this paper
• Contribution of anorexia to tissue wasting in cachexia

  2010cited by this paper
• Consensus on cachexia definitions.

  2010cited by this paper
• Cardiac alterations in cancer-induced cachexia in mice.

  2010cited by this paper
• Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia

  2010cited by this paper
• Are tumoral factors responsible for host tissue wasting in cancer cachexia?

  2010cited by this paper
• Signaling pathways perturbing muscle mass

  2010cited by this paper
• Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients.

  2009cited by this paper
• Functional brown adipose tissue in healthy adults.

  2009cited by this paper
• Sarcoplasmic Reticulum-Mitochondrial Symbiosis: Bidirectional Signaling in Skeletal Muscle

  2009cited by this paper
• Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs

  2009cited by this paper
• Sarcoplasmic reticulum-mitochondrial through-space coupling in skeletal muscle.

  2009cited by this paper
• Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group.

  2009cited by this paper
• During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation

  2009cited by this paper
• The role of cytokines in cancer cachexia

  2009cited by this paper
• Regulation of mitofusin-2 expression in skeletal muscle.

  2009cited by this paper
• Cachexia: a new definition.

  2008cited by this paper
• Catabolic mediators of cancer cachexia

  2008cited by this paper
• Adipokines and ghrelin in gastric cancer cachexia.

  2008cited by this paper
• Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors

  2007cited by this paper
• The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia.

  2007cited by this paper
• Myoglobin plasma level related to muscle mass and fiber composition – a clinical marker of muscle wasting?

  2007cited by this paper
• Targets in clinical oncology: the metabolic environment of the patient.

  2007cited by this paper
• Symptom prevalence in patients with incurable cancer: a systematic review.

  2007cited by this paper
• The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle.

  2007cited by this paper
• Mechanisms to explain wasting of muscle and fat in cancer cachexia

  2007cited by this paper
• FoxO3 controls autophagy in skeletal muscle in vivo.

  2007cited by this paper
• Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.

  2007cited by this paper
• Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists.

  2007cited by this paper
• Are Peroxisome Proliferator-Activated Receptors Involved in Skeletal Muscle Wasting during Experimental Cancer Cachexia? Role of B 2 -Adrenergic Agonists

  2007cited by this paper
• Overexpression of peroxisome proliferator-activated receptor gamma co-activator-1alpha leads to muscle atrophy with depletion of ATP.

  2006cited by this paper
• Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

  2006cited by this paper
• Overexpression of Peroxisome Proliferator-Activated Receptor γ Co-Activator-1α Leads to Muscle Atrophy with Depletion of ATP

  2006cited by this paper
• Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis.

  2005cited by this paper
• Cross‐talk between skeletal muscle and adipose tissue: A link with obesity?

  2005cited by this paper
• Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake

  2005cited by this paper
• Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.

  2004cited by this paper
• IKKbeta/NF-kappaB activation causes severe muscle wasting in mice.

  2004cited by this paper
• Cancer anorexia-cachexia syndrome: cytokines and neuropeptides

  2004cited by this paper
• Effect of zinc-alpha2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue.

  2004cited by this paper
• Effect of zinc-α2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue

  2004cited by this paper

• The Vesicular Intersection Layer: A Framework for Cross-Kingdom Extracellular Vesicle Signaling That May Connect Gut Dysbiosis to Skeletal Muscle Wasting in Colorectal Cancer Cachexia

  2026cites this paper
• Immunonutrition interventions for sarcopenia in cancer patients: A systematic review and meta-analysis of randomized controlled trials

  2026cites this paper
• Human neuromuscular organoids mimic cancer-induced muscle cachexia.

  2026cites this paper
• Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab

  2026cites this paper
• Fiber-type vulnerability and proteostasis reprogramming in skeletal muscle during pancreatic cancer cachexia.

  2026cites this paper
• The Role of Dietary Care in Improving the Quality of Life of Patients Undergoing Chemotherapy for Gastrointestinal Tumours.

  2026cites this paper
• NF-κB Signaling as a Central Driver of Cancer Cachexia.

  2026cites this paper
• Circulating Inflammatory and Mitochondrial Biomarkers Associated with Cachexia in Advanced Non-Small Cell Lung Cancer.

  2026cites this paper
• The impact of cachexia index combined with BMI trajectory on survival outcomes in patients with cancer cachexia

  2026cites this paper
• Impact of pre-therapeutic fasting plasma glucose on survival outcomes in advanced non-small cell lung cancer patients

  2026cites this paper
• Tumor-Intrinsic Transcriptional Signatures Linked to Cachexia Induction and Chemotherapy Response in Paired Human Neuroendocrine Carcinoma Cell Lines

  2026cites this paper
• Prognostic Impact of Cachexia Index in Patients Undergoing Surgery for Esophageal Cancer.

  2026cites this paper
• Patient-derived organoid xenografts model esophageal cancer cachexia and enable assessment of anti-inflammatory drug repositioning

  2026cites this paper
• Cancer cachexia: molecular basis and therapeutic advances

  2026cites this paper
• Association of Adipose Tissue Activity in Cervical Regions with Weight Loss and Prognostic Survival in Gastric Cancer Patients.

  2026cites this paper
• Sarcopenia and recurrence risk in high-risk non–muscle-invasive bladder cancer: a nonlinear modeling approach

  2026cites this paper
• BMV and CCMV-Based Viral Nanoparticles for Delivery of N -Desmethyl-Tamoxifen as Treatment of Triple-Negative Breast Cancer

  2026cites this paper
• Role of mitochondrial dysfunction in muscle wasting in cancer cachexia: a narrative review.

  2026cites this paper
• Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels.

  2026cites this paper
• Identification of circulating lipidomic biomarkers of malnutrition risk among oncology patients in the Total Cancer Care (TCC) Study: a Cross-Sectional Analysis

  2026cites this paper
• FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities

  2026cites this paper
• Metastatic Spine Disease Alters Vertebral Load‐To‐Strength Ratios in Cancer Patients Compared to Healthy Individuals

  2026cites this paper
• Structured Exercise During Chemotherapy for Locally Advanced or Metastatic Pancreatic Cancer: A Single‐Arm, Feasibility Trial

  2026cites this paper
• The S100A8/A9 complex promotes food intake and prevents adipose tissue loss during cancer cachexia in mice.

  2026cites this paper
• CircularRNA and Musculoskeletal Diseases.

  2025cites this paper
• Prognostic significance of anthropometric measurements in gastric cancer: a multicenter cohort study

  2025cites this paper
• Cachexia index as a biomarker for cancer cachexia and quality of life in patients with gastric cancer

  2025cites this paper
• Alpha‐Ketoisocaproate Attenuates Muscle Atrophy in Cancer Cachexia Models

  2025cites this paper
• Ruxolitinib alleviated muscle atrophy in cancer cachexia by inhibiting IL-6/JAK/STAT3 signaling pathway in mice.

  2025cites this paper
• Nutraceutical Interception of Cachexia: Grape-Derived Compounds as Pathophysiological Network Modulators

  2025influential citation
• Transcriptome and microRNAome profiling of human skeletal muscle in pancreatic cancer cachexia

  2025cites this paper
• Bridging the tumor microenvironment: the pivotal role of cancer-associated fibroblasts in tumor cachexia development

  2025cites this paper
• Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.

  2025cites this paper
• What Cachexia-Related Outcomes Are Measured in Lung Cancer Chemotherapy Clinical Trials?

  2025cites this paper
• Molecular recognition of two approved drugs Macimorelin and Anamorelin by the growth hormone secretagogue receptor

  2025cites this paper
• From brain-sparing to prioritised tumour growth: Insights into tumour-host interactions.

  2025cites this paper
• FLOT chemotherapy treatment affects adipocyte’s lipid metabolism: an in vitro study

  2025cites this paper
• Global epidemiological characteristics of malnutrition in cancer patients: a comprehensive meta-analysis and systematic review

  2025cites this paper
• Management of Anorexia–Cachexia Syndrome in a Community Palliative Care Support Team

  2025cites this paper
• Skeletal muscle endothelial dysfunction through the activin A–PGC1α axis drives progression of cancer cachexia

  2025cites this paper
• The canonical ER stress IRE1α/XBP1 pathway mediates skeletal muscle wasting during pancreatic cancer cachexia

  2025cites this paper
• Elucidating the role of fatty acid reprogramming in ovarian cancer: insights cross-talk between blood, subcutaneous fat, and ovarian cancer tissues

  2025cites this paper
• Efek Samping Kombinasi Doxorubicin dan Cyclophosphamide pada Pasien Kanker Payudara: Studi Kasus

  2025cites this paper
• Cucurbitacin B induces oral squamous cell carcinomapyroptosis via GSDME and inhibits tumour growth

  2025cites this paper
• The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy

  2025cites this paper
• Coptis japonica Makino ethanol extracts attenuates cancer cachexia induced muscle and fat wasting through inhibition of the STAT3 signaling pathway

  2025cites this paper
• Effect of Turmeric (Curcumin) on Cancer Patients: A Comprehensive Review of its Anticancer Mechanisms, Clinical Efficacy, and Potential Therapeutic Applications

  2025cites this paper
• Prognostic value of combining preoperative immune-inflammatory-nutritional index and tumor biomarkers in gastric cancer patients undergoing radical resection

  2025cites this paper
• A comparison of human skeletal muscle cell maturation in 2D versus 3D culture: A quantitative proteomic study

  2025cites this paper
• The role of NAD+ metabolism and its modulation of mitochondria in aging and disease

  2025cites this paper
• The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma.

  2025cites this paper
• Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study

  2025cites this paper
• Unraveling the role of STAT3 in Cancer Cachexia: pathogenic mechanisms and therapeutic opportunities

  2025cites this paper
• Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia.

  2025cites this paper
• Preoperative albumin-to-fibrinogen ratio as a predictor of postoperative hospital stay in locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy

  2025cites this paper
• Cancer therapy and cachexia

  2025cites this paper
• Promoting mitochondrial fusion is protective against cancer-induced muscle detriments in males and females

  2025cites this paper
• A JAK/STAT-Pdk1-S6K axis bypasses systemic growth restrictions to promote regeneration

  2025cites this paper
• Modified Naples Prognostic Score for Postoperative Prognostic Stratification in Patients with Oral Squamous Cell Carcinoma

  2025cites this paper
• Physical Activity, Exerkines, and Their Role in Cancer Cachexia

  2025cites this paper
• General disease symptoms and their impact on appetite and food intake in older hospitalized patients.

  2025cites this paper
• Multi-omics characterization of cachexia-related genes reveals prognostic signatures and immune landscape in breast cancer

  2025cites this paper
• Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways

  2025cites this paper
• Exploring SGLT2 Inhibitors' Activity in Breast Cancer: An Overview.

  2025cites this paper
• Myocellular adaptations to short-term weighted wheel-running exercise are largely conserved during C26-tumour induction in male and female mice.

  2025cites this paper
• TRIM22 governs tumorigenesis and protects against endometrial cancer-associated cachexia by inhibiting inflammatory response and adipose thermogenic activity

  2025cites this paper
• An Overview of Sarcopenia: Focusing on Nutritional Treatment Approaches

  2025cites this paper
• A neuroimmune circuit mediates cancer cachexia-associated apathy.

  2025cites this paper
• Miraculin Can Contribute to a Reduction in Inflammatory Biomarkers and Cachexia in Malnourished Patients with Cancer and Taste Disorders

  2025cites this paper
• Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy

  2025cites this paper
• Impact of Cancer Cachexia Progression on OATP1B1 Transport Activity: Quantitative Analysis Using Coproporphyrin‐I as an Endogenous Biomarker

  2025cites this paper
• The Molecular Mechanisms and Treatment of Cancer-Related Cachexia.

  2025cites this paper
• Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma.

  2025cites this paper
• The Dynamic Role of Ferroptosis in Cancer Immunoediting: Implications for Immunotherapy.

  2025cites this paper
• Prevalence and prognostic significance of cachexia diagnosed by novel definition for Asian population among Chinese cirrhotic patients.

  2025cites this paper
• Connection between nutrition and oncology in dogs and cats: perspectives, evidence, and implications—a comprehensive review

  2025cites this paper
• The influencing factors of tumor-related sarcopenia: a scoping review

  2025cites this paper
• Inflammatory marker cut-off points and prognosis in incurable cancer: validation study

  2025cites this paper
• Establishment and characterization of novel cancer cachexia-inducing cell line, Aku60GC, of scirrhous gastric cancer

  2025cites this paper
• The Optimal Timing for Initiating Anamorelin in the Treatment of Cancer Cachexia

  2025cites this paper
• Cancer Cachexia: Causes and Therapeutic Strategies

  2025cites this paper
• Integrative metabolic profiling of hypothalamus and skeletal muscle in a mouse model of cancer cachexia.

  2025cites this paper
• Oxidant-Based Cytotoxic Agents During Aging: From Disturbed Energy Metabolism to Chronic Inflammation and Disease Progression

  2025cites this paper
• How the ghrelin receptor recognizes the acyl-modified orexigenic hormone

  2025cites this paper
• A higher preoperative cachexia index can result in the sufficient administration of S-1 adjuvant chemotherapy and lead to a good prognosis for elderly patients with stage II/III gastric cancer

  2025cites this paper
• GL261 glioblastoma induces delayed body weight gain and stunted skeletal muscle growth in young mice.

  2025cites this paper
• Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies.

  2025cites this paper
• Association between the Pretreatment Body Mass Index and Anamorelin's Efficacy in Patients with Cancer Cachexia: A Retrospective Cohort Study.

  2025cites this paper
• Prognostic value of the pretreatment Glasgow prognostic score or modified Glasgow prognostic score in patients with advanced cancer receiving immune checkpoint inhibitors: A systematic review and meta‑analysis

  2025cites this paper
• Cisplatin‐Induced Muscle Wasting and Atrophy: Molecular Mechanism and Potential Therapeutic Interventions

  2025cites this paper
• Wide-range and high-throughput quantification of anamorelin in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry.

  2025cites this paper
• Effect of anamorelin treatment duration on survival of patients with cancer cachexia: A retrospective study

  2025cites this paper
• Global mitophagy inhibition via BNIP3 ablation is not sufficient to alleviate skeletal muscle impairments in male and female tumor-bearing mice.

  2025cites this paper
• Beyond Performance: Creatine Delays the Onset of Fatigue and Augments Muscle Regeneration in Doxorubicin-Induced Myotoxicity

  2025cites this paper
• Ovarian cancer and malnutrition: a literature review

  2025cites this paper
• Bu-zhong-yi-qi decoction regulates JNK/c-JUN signaling pathway to improve skeletal muscle atrophy caused by cancer cachexia.

  2025cites this paper
• Cachexia index as a prognostic marker in patients undergoing biliary tract cancer resection

  2025cites this paper
• Chronic Fatigue in Cancer Survivorship: Psychiatry Versus Oncology or Psychiatry with Oncology?

  2025cites this paper
• Modulating the Gut–Muscle Axis: Increasing SCFA-Producing Gut Microbiota Commensals and Decreasing Endotoxin Production to Mitigate Cancer Cachexia

  2025cites this paper
• Prognostic impact of preoperative cachexia in patients undergoing major hepatopancreatobiliary surgery for malignancy.

  2025cites this paper